| 3.13 0.04 (1.29%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.83 | 1-year : | 7.77 |
| Resists | First : | 4.99 | Second : | 6.65 |
| Pivot price | 4.36  |
|||
| Supports | First : | 2.3 | Second : | 1.92 |
| MAs | MA(5) : | 3.68 |
MA(20) : | 4.19 |
| MA(100) : | 11.55 |
MA(250) : | 39.49 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.9  |
| %K %D | K(14,3) : | 3 |
D(3) : | 16.6 |
| RSI | RSI(14): 33.4 |
|||
| 52-week | High : | 223.6 | Low : | 2.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SLXN ] has closed above bottom band by 6.2%. Bollinger Bands are 45.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.19 - 3.21 | 3.21 - 3.22 |
| Low: | 2.97 - 2.98 | 2.98 - 3 |
| Close: | 3.11 - 3.13 | 3.13 - 3.15 |
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Fri, 12 Jun 2026
Silexion Therapeutics (NASDAQ: SLXN) registers up to 859,609 resale shares - Stock Titan
Wed, 10 Jun 2026
Silexion Therapeutics Corp Ord Stock Short Interest Falls to 43.76% - Quiver Quantitative
Mon, 08 Jun 2026
Number of shareholders of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView
Mon, 08 Jun 2026
Silexion (SLXN) awards CSO 6,000 RSUs after reverse share split - Stock Titan
Fri, 29 May 2026
Silexion Therapeutics (SLXN) completes 1-for-10 reverse split, adjusts warrant terms - Stock Titan
Tue, 26 May 2026
Silexion Therapeutics to implement 1-for-10 reverse share split, effective May 29, 2026 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 8 (%) |
| Held by Institutions | 4.5 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | -59.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.82 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -123.3 % |
| Return on Equity (ttm) | -897.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -30.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.06 |
| PEG Ratio | 0 |
| Price to Book value | 3.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|